Axel Horns presents in his blog http://www.ipjur.com/blog2/index.php?/archives/165-German-Bundestag-Meets-Innovation.html#extended two Bundestag incidents illustrating to him the parliament’s attitude towards innovation.One is a mini-scandal raised after a MP read his speech from an iPad, the other is of treating the Internet as a potential hazard. For him it goes to show that “the innovative digital world of the future is shaped elsewhere, mainly in the United States, and not in Europe, let alone in Germany” and yet I’m not sure that in innovative Israel the parliament is more enlightened on these themes…

I’d like to invite you to our new Fisher Weiler Jones group on LinkedIn, which will provide you with updates from our staff and networking opportunities.
Please feel free to invite colleagues and business partners to the group, and to raise topics for discussion and general interest. Ideas for improving the group are very welcome.
I hope you will benefit from the group.

Patently-O prepared a list – of most cited patent cases in the last few years.
These represent current patent issues and themes in the field.

Graham v. John Deere is the oldest case, of the last few years the following cases appear: Phillips v. AWH Corp., KSR Intern. Co. v. Teleflex Inc., MedImmune, Inc. v. Genentech, Inc., and In re Seagate Technology, LLC.

Nature Biotechnology (28: 381) has published an article discussing the prospects of gene patents for diagnostics, following the decision against Myriad Genetics regarding BRCA1 and BRCA2 genetic tests for familial breast and ovarian cancer.

The decision reflects the controversy around gene patents, and is discussed in its moral and business contexts.The article concludes “As we move from single-gene tests to multiple-gene signature testing and whole genome sequencing, it might also be possible to assign rights according to the importance of any specific gene sequence in the utility of the test.

Such a principle, instead of rewarding companies that managed to surround the early gene mutant discoveries (which now look rather trivial) with an impenetrable wall of IP, would incentivize those who continue to develop tests of high medical value with commensurate financial remuneration. That this ideal is implausible within the current petrified patent system and commercial infrastructure doesn’t have to stop the dream, and certainly shouldn’t stop the discussion.”

Approval of technical effect in claims dealing purely with networked computer systems processing HTML and/or XML documents, on grounds that the improving of high level performance of computer system is a technical problem, when related to limited resources.

http://www.ipjur.com/blog2/index.php?/archives/153-German-Supreme-Court-on-Patents-on-Computer-Implemented-Inventions.html